Improving treatment of non-small cell lung cancer: suppressing cell division cycle associated protein 3 (CDCA3)

改善非小细胞肺癌的治疗：抑制细胞分裂周期相关蛋白 3 (CDCA3)

• 批准号: nhmrc : GNT1127825
• 负责人: Dr Mark Adams
• 金额: $ 19.44万
• 依托单位: Queensland University of Technology
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/improving-treatment-non-3-cdca3/1347646
• 关键词: Improving; treatment; non; small; cell

Lung cancer is the leading cause of cancer-related mortality worldwide. This project will establish the worth of suppressing the molecule ‘cell division cycle associated protein 3’ (CDCA3) in lung cancer. To do so, we will adjust the levels of CDCA3 in animal lung cancer models and treat the tumours with chemotherapy and the novel drug CX-4945. We expect that reduced levels of CDCA3 combined with CX-4945 and/or chemotherapy in NSCLC patients will benefit patient outcome.

肺癌是全球癌症相关死亡的主要原因。本项目将确定抑制分子“细胞分裂周期相关蛋白3”（CDCA3）在肺癌中的价值。为此，我们将调整动物肺癌模型中CDCA3的水平，并用化疗和新药CX-4945治疗肿瘤。我们预计，降低CDCA3水平联合CX-4945和/或化疗将有利于非小细胞肺癌患者的预后。